What
Where
PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers
(Expired)From: Federal Government(Federal)
 Basic Details |  Start Date05 Jul, 2018 (about 5 years ago) Due Date19 Jul, 2018 (about 5 years ago) TypeBid NotificationIdentifierN01CN5503-16 | ||||
 Customer / Agency | Department of Health and Human Services | ||||
Attachments (1) | |||||
Unlock the best of InstantMarkets.Please Sign In to see more out of InstantMarkets such as history, intelligent business alerts and many more.
Don't have an account yet? Create a free account now.
Please see attached Justification & Approval for PREVENT Preclinical Drug Development: Preclinical Efficacy and Intermediate Endpoint
Location
Place Of Performance : 9609 Medical Center Drive, Room 1E128 Rockville, Maryland 20852 United States
Country : United StatesYou may also like
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF ...
Due: 07 Jan, 2025 (in 8 months)PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER
Due: 15 Sep, 2024 (in 4 months)BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: COLORECTAL CANCER (CRC) PR...
Due: 10 Sep, 2026 (in about 2 years)Please Sign In to see more like these.
Don't have an account yet? Create a free account now.